B-MoGen has acquired an exclusive license to Mayo Clinic technology that allows precise introduction of deletions into the mitochondrial genome of living cells. This technology includes a selection approach that allows one to shift the levels of heteroplasmy toward the altered mitochondrial genome in a population of cells. Our technology is based on modified TAL endonucleases and is the first of its kind. Our unique mitochondrial gene editing allows detailed studies of mitochondrial gene function and CIS regulatory sequences. Furthermore, in ongoing work at B-MoGen, this technology is paving the way toward precise mitochondrial gene editing with single base resolution.